Trial Profile
Post-authorisation Safety Cohort Observation Of Retacrit (tm) (Epoetin Zeta) Administered Subcutaneously For The Treatment Of Renal Anaemia (Pasco II)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Epoetin zeta (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Acronyms PASCO II
- Sponsors Pfizer
- 05 Mar 2023 Results ( N=6,346 ) assessing safety cohort observation of Retacrit and Silapo (epoetin-zeta) administered subcutaneously for the treatment of renal anemia, published in the Clinical Nephrology.
- 08 Jun 2020 Status changed from active, no longer recruiting to completed.
- 18 Feb 2019 Planned End Date changed from 1 Apr 2022 to 30 Apr 2022.